- Home
- RMCO vs SABS Comparison
RMCO vs SABS Comparison
Compare RMCO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- SABS
- Stock Information
- Founded
- RMCO 2021
- SABS 2014
- Country
- RMCO United States
- SABS United States
- Employees
- RMCO N/A
- SABS N/A
- Industry
- RMCO Multi-Sector Companies
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- SABS Health Care
- Exchange
- RMCO Nasdaq
- SABS Nasdaq
- Market Cap
- RMCO 14.9M
- SABS 15.8M
- IPO Year
- RMCO N/A
- SABS N/A
- Fundamental
- Price
- RMCO $1.25
- SABS $1.78
- Analyst Decision
- RMCO
- SABS Strong Buy
- Analyst Count
- RMCO 0
- SABS 5
- Target Price
- RMCO N/A
- SABS $11.80
- AVG Volume (30 Days)
- RMCO 18.6K
- SABS 18.6K
- Earning Date
- RMCO 08-14-2025
- SABS 08-07-2025
- Dividend Yield
- RMCO N/A
- SABS N/A
- EPS Growth
- RMCO N/A
- SABS N/A
- EPS
- RMCO N/A
- SABS N/A
- Revenue
- RMCO $1,568,212.00
- SABS $377,835.00
- Revenue This Year
- RMCO N/A
- SABS N/A
- Revenue Next Year
- RMCO N/A
- SABS N/A
- P/E Ratio
- RMCO N/A
- SABS N/A
- Revenue Growth
- RMCO 204.08
- SABS N/A
- 52 Week Low
- RMCO $0.74
- SABS $1.00
- 52 Week High
- RMCO $1.32
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- RMCO 62.27
- SABS 49.33
- Support Level
- RMCO $1.19
- SABS $1.60
- Resistance Level
- RMCO $1.30
- SABS $1.87
- Average True Range (ATR)
- RMCO 0.06
- SABS 0.11
- MACD
- RMCO 0.02
- SABS -0.01
- Stochastic Oscillator
- RMCO 80.00
- SABS 62.07
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.